Intracellular transport, organelle biogenesis and establishment of Golgi identity: impact of brefeldin A on the activity of lipid synthesizing enzymes.
1. The effect of brefeldin A (BFA) on generation of transport vesicles, synthesis of phosphoglycerides, sphingosine and ceramides, and utilization of the sphingolipid precursors in the formation of sphingomyelin and glycosphingolipids in Golgi was investigated. 2. In the presence of 5-10 micrograms/ml BFA, the incorporation of [3H]palmitate into glycerides, phosphoglycerides and sphingolipids decreased 45-60%, and the production of endoplasmic reticulum transport vesicles was reduced 30-50%. 3. In Golgi membranes, the presence of 5-10 micrograms/ml BFA in the mixture, assembled to generate Golgi vesicles, evoked inhibitory effect on the synthesis of sphingomyelin, glycosphingolipids and phosphatidylcholine. On average, the synthesis of the sphingolipids and phosphatidylcholine and production of Golgi transport vesicles declined to 30-40%. 4. Addition of 5-10 micrograms/ml BFA to the assay mixture prepared to measure the activity of cytidylyltransferase, phosphocholine diacylglyceroltransferase, and serine palmitoyltransferase, caused up to 50% inhibition of the enzymes involved in the synthesis of phosphatidylcholine and up to 70% inhibition of the enzyme generating 3-ketosphinganine. 5. The results suggest that BFA inhibits the synthesis of phosphoglycerides and sphingolipids. This, at first, is displayed in reduced production of endoplasmic reticulum and Golgi transport vesicles, while the depletion of sphingolipids abrogates the identity of Golgi membranes.
Slomiany
A
A
Research Center, University of Medicine and Dentistry of New Jersey, New Jersey Dental School, Newark 07103-2400.
Grabska
M
M
Slomiany
B A
BA
Grzelinska
E
E
Morita
M
M
Slomiany
B L
BL
D000217:Acyltransferases / Q000037:antagonists & inhibitors; D001345:Autoradiography; D020126:Brefeldin A; D002458:Cell Fractionation; D002518:Ceramides / Q000096:biosynthesis; D019916:Choline-Phosphate Cytidylyltransferase; D003517:Cyclopentanes / Q000494:pharmacology*; D002798:Diacylglycerol Cholinephosphotransferase / Q000037:antagonists & inhibitors; D004591:Electrophoresis, Polyacrylamide Gel; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism*; D005994:Glycerophosphates / Q000096:biosynthesis*; D006031:Glycosylation; D006056:Golgi Apparatus / Q000187:drug effects* / Q000378:metabolism; D008563:Membrane Lipids / Q000096:biosynthesis*; D009713:Nucleotidyltransferases / Q000037:antagonists & inhibitors; D010713:Phosphatidylcholines / Q000096:biosynthesis; D051102:Serine C-Palmitoyltransferase; D013107:Sphingolipids / Q000096:biosynthesis*; D013110:Sphingosine / Q000378:metabolism
D002518:Ceramides; D003517:Cyclopentanes; D005994:Glycerophosphates; D008563:Membrane Lipids; D010713:Phosphatidylcholines; D013107:Sphingolipids; D020126:Brefeldin A; D000217:Acyltransferases; D051102:Serine C-Palmitoyltransferase; D009713:Nucleotidyltransferases; D019916:Choline-Phosphate Cytidylyltransferase; D002798:Diacylglycerol Cholinephosphotransferase; D013110:Sphingosine